Cargando…
Predicting efficacy of epirubicin by a multigene assay in advanced breast cancer within a Danish Breast Cancer Cooperative Group (DBCG) cohort: a retrospective-prospective blinded study
PURPOSE: Anthracyclines remain a cornerstone in the treatment of primary and advanced breast cancer (BC). This study has evaluated the predictive value of a multigene mRNA-based drug response predictor (DRP) in the treatment of advanced BC with epirubicin. The DRP is a mathematical method combining...
Autores principales: | Buhl, Anna Sofie Kappel, Christensen, Troels Dreier, Christensen, Ib Jarle, Nelausen, Knud Mejer, Balslev, Eva, Knoop, Ann Søegaard, Brix, Eva Harder, Svensson, Else, Glavicic, Vesna, Luczak, Adam, Langkjer, Sven Tyge, Linnet, Søren, Jakobsen, Erik Hugger, Bogovic, Jurij, Ejlertsen, Bent, Rasmussen, Annie, Hansen, Anker, Knudsen, Steen, Nielsen, Dorte, Jensen, Peter Buhl |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6208899/ https://www.ncbi.nlm.nih.gov/pubmed/30099635 http://dx.doi.org/10.1007/s10549-018-4918-4 |
Ejemplares similares
-
Tumour-infiltrating lymphocytes and response to neoadjuvant letrozole in patients with early oestrogen receptor-positive breast cancer: analysis from a nationwide phase II DBCG trial
por: Skriver, Signe Korsgaard, et al.
Publicado: (2020) -
The Prosigna 50-gene profile and responsiveness to adjuvant anthracycline-based chemotherapy in high-risk breast cancer patients
por: Jensen, Maj-Britt, et al.
Publicado: (2020) -
First-Line Treatment of HER2-Positive Metastatic Breast Cancer With
Dual Blockade Including Biosimilar Trastuzumab (SB3): Population-Based
Real-World Data From the DBCG
por: Celik, Alan, et al.
Publicado: (2022) -
Does timing of adjuvant chemotherapy influence the prognosis after early breast cancer? Results of the Danish Breast Cancer Cooperative Group (DBCG)
por: Cold, S, et al.
Publicado: (2005) -
Two open-label, single arm, non-randomized phase II studies of irinotecan for the treatment of metastatic breast cancer in patients with increased copy number of the topoisomerase I gene
por: Kümler, Iben, et al.
Publicado: (2019)